Latest News
Most Supplement Companies Skip the RCT
Most Supplement Companies Skip the RCT. Here’s Why the Few That Don’t Often Get It Wrong The industry’s uncomfortable truth The global dietary supplement market is worth hundreds of billions of dollars.[1] Brands make claims about energy, cognition, immunity, and...
Latest News
Doctor, Patient, Agent: A New Clinical Triad for Medicine
By 6:45 AM, the dashboard is already waiting. A longevity physician sits down with coffee and reads what the monitoring agent assembled overnight: a falling seven-day HRV trend in a patient recovering from a viral illness, a queued statin titration for a...
Physiology: The Missing Layer in Precision Medicine
Precision medicine has been positioned as one of the most promising evolutions in modern healthcare. Gene panels. Liquid biopsies. Microbiome-targeted therapies. Multi-omics integration. The premise is compelling: the more precisely we can characterize biological...
Weekly News Roundup | 27 April 2026
Life science news 27 April 2026: Eli Lilly's $7 billion in vivo CAR-T deal, Trump's psychedelics executive order and a first-ever gene therapy for hearing loss headline a landmark week across global life science. Eli Lilly announced on 20 April its acquisition of...
Life Science Daily News: Join the Community
A Community-Driven Hub for Life Sciences News and Discovery In an era of rapid scientific progress and near-constant breakthroughs, having a reliable, inclusive platform to share and explore life-sciences news is more important than ever. Life Science Daily News...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Clinical Trials Roundup | 24 April 2026
Neurona Therapeutics' rezanecel demonstrates durable seizure reduction past the one-year mark in drug-resistant mesial temporal lobe epilepsy at the AAN Annual Meeting, Gilead Sciences and Arcus Biosciences' TIGIT inhibitor domvanalimab fails its pivotal Phase 3 lung...
AstraZeneca’s $18.5 Billion China Obesity Drug Deal Explained
AstraZeneca China Obesity Drug Deal: A $18.5 Billion Bet on the Future of Weight Management AstraZeneca announced on 30 January 2026, what has quickly become known as the AstraZeneca CSPC obesity deal, a landmark licensing and collaboration agreement with China's CSPC...
Beyond Words: AI, Human-Centered Design, and the Future of Health Literacy
The Evolving Definition of Health Literacy In August 2020, the Centers for Disease Control and Prevention (CDC) updated its definition of health literacy, emphasizing the ability to use health information effectively (CDC). This shift highlights that merely...
The iPS Era is Arriving – Now the Field Must Prove it Can Scale
For years, induced pluripotent stem cells, or iPS cells, have stood for one of the most ambitious ideas in modern medicine - that it may be possible to create replacement human cells on-demand and use them to restore lost function in the body. With 20 years of history...
Boehringer Ingelheim Opens AI Centre in London’s Knowledge Quarter
Boehringer Ingelheim AI Centre London: A New Frontier for Pharmaceutical Research German biopharmaceutical company Boehringer Ingelheim announced on 20 April 2026 the launch of a new centre for artificial intelligence and machine learning in King's Cross, London, as...
Tumor Vasculature has Long Been a Target. Measuring it is the Next Step
Oncology drug development is more mechanistically advanced than ever. Scientists and researchers design therapies to block immune evasion, disrupt tumor metabolism, and rewire the microenvironment. Yet a costly problem remains: many patients who should respond to...
When ADHD and Menopause Overlap
When ADHD and Menopause Overlap: Why Midlife Women Are Still Not Getting the Right Answers Girls and women have historically been overlooked in the ADHD diagnostic process and this is due, in part, to the fact that their symptoms often present differently than they do...
How Rapid Access MRI Can Reshape Diagnostic Pathways
It’s no secret that the National Health Service (NHS) is suffering diagnostic pressure. The British Medical Association (BMA) reports that in November 2024, approximately 1.6 million people in England were waiting for a diagnostic test. That’s double the 0.8...
Panthera Biopartners Expands European Footprint
Panthera Biopartners Expands European Footprint with Acquisition of Hungary’s Leading Clinical Research Organisation, OEC Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners...
Inside the Science: The Hydrogel Injection Targeting NHS Knee Care
Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS A new white paper entitled “Inside the Science: A Major Step Forward for Knee...
Women’s Health Strategy England: Ten Years of Planned Reform
England's Renewed Women's Health Strategy Puts Patient Voice at the Centre of Care The government published the renewed Women's Health Strategy for England on 15 April 2026, setting out a ten-year programme to address deep-rooted failures in how the NHS identifies,...
NHS England First in World to Offer Blenrep for Myeloma
Blenrep Multiple Myeloma NHS England Rollout Makes UK a World First in Blood Cancer Treatment England has become the first country in the world to make GSK's belantamab mafodotin, marketed as Blenrep, available to multiple myeloma patients through a national health...
Clinical Trials Roundup | 24 April 2026
Neurona Therapeutics' rezanecel demonstrates durable seizure reduction past the one-year mark in drug-resistant mesial temporal lobe epilepsy at the AAN Annual Meeting, Gilead Sciences and Arcus Biosciences' TIGIT inhibitor domvanalimab fails its pivotal Phase 3 lung...
AstraZeneca’s $18.5 Billion China Obesity Drug Deal Explained
AstraZeneca China Obesity Drug Deal: A $18.5 Billion Bet on the Future of Weight Management AstraZeneca announced on 30 January 2026, what has quickly become known as the AstraZeneca CSPC obesity deal, a landmark licensing and collaboration agreement with China's CSPC...
Beyond Words: AI, Human-Centered Design, and the Future of Health Literacy
The Evolving Definition of Health Literacy In August 2020, the Centers for Disease Control and Prevention (CDC) updated its definition of health literacy, emphasizing the ability to use health information effectively (CDC). This shift highlights that merely...
The iPS Era is Arriving – Now the Field Must Prove it Can Scale
For years, induced pluripotent stem cells, or iPS cells, have stood for one of the most ambitious ideas in modern medicine - that it may be possible to create replacement human cells on-demand and use them to restore lost function in the body. With 20 years of history...
Boehringer Ingelheim Opens AI Centre in London’s Knowledge Quarter
Boehringer Ingelheim AI Centre London: A New Frontier for Pharmaceutical Research German biopharmaceutical company Boehringer Ingelheim announced on 20 April 2026 the launch of a new centre for artificial intelligence and machine learning in King's Cross, London, as...
Tumor Vasculature has Long Been a Target. Measuring it is the Next Step
Oncology drug development is more mechanistically advanced than ever. Scientists and researchers design therapies to block immune evasion, disrupt tumor metabolism, and rewire the microenvironment. Yet a costly problem remains: many patients who should respond to...
When ADHD and Menopause Overlap
When ADHD and Menopause Overlap: Why Midlife Women Are Still Not Getting the Right Answers Girls and women have historically been overlooked in the ADHD diagnostic process and this is due, in part, to the fact that their symptoms often present differently than they do...
How Rapid Access MRI Can Reshape Diagnostic Pathways
It’s no secret that the National Health Service (NHS) is suffering diagnostic pressure. The British Medical Association (BMA) reports that in November 2024, approximately 1.6 million people in England were waiting for a diagnostic test. That’s double the 0.8...
Panthera Biopartners Expands European Footprint
Panthera Biopartners Expands European Footprint with Acquisition of Hungary’s Leading Clinical Research Organisation, OEC Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners...
Inside the Science: The Hydrogel Injection Targeting NHS Knee Care
Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS A new white paper entitled “Inside the Science: A Major Step Forward for Knee...
Women’s Health Strategy England: Ten Years of Planned Reform
England's Renewed Women's Health Strategy Puts Patient Voice at the Centre of Care The government published the renewed Women's Health Strategy for England on 15 April 2026, setting out a ten-year programme to address deep-rooted failures in how the NHS identifies,...
NHS England First in World to Offer Blenrep for Myeloma
Blenrep Multiple Myeloma NHS England Rollout Makes UK a World First in Blood Cancer Treatment England has become the first country in the world to make GSK's belantamab mafodotin, marketed as Blenrep, available to multiple myeloma patients through a national health...
Featured Articles
Further News
Weekly News Roundup | 20 April 2026
Life science news 20 April 2026: A landmark pancreatic cancer breakthrough, record-breaking biotech IPO, major UK investment announcements and a surge in FDA approvals define a momentous week for the global life science industry. Revolution Medicines reported on 13...
Yaqrit Phase 2a Data, Clinical Consensus Boost YAQ007 and YAQ006 in HE
• Strong global consensus on measurement and role of ammonia in Hepatic Encephalopathy (HE) • Phase 2a results of YAQ007 (oral OPA) show ammonia reduction • Utility of rifaximin in HE defined more narrowly LONDON, April 17, 2026 (GLOBE NEWSWIRE) -- Yaqrit, a...
Strait of Hormuz Closure: The Threat to Global Medicine Supplies
When US and Israeli military operations against Iran began on 28 February 2026, the consequences for global energy markets were immediate and predictable. What was less widely anticipated was the scale of the disruption now rippling through the life sciences sector....
Clinical Trials Roundup | 17 April 2026
Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...
UK Government’s LSLIP: A New Era for British Life Science
UK Government's Life Sciences Large Investment Portfolio: A New Era for British Life Science The United Kingdom's life sciences sector received a significant policy boost on 14 April 2026 when the government formally announced the Life Sciences Large Investment...
The UK Spine Crisis: Beyond Posture to a Future of Regenerative Care
The UK is currently navigating a silent epidemic that threatens not only our collective physical well-being but also our national productivity and the long-term sustainability of our healthcare infrastructure. Musculoskeletal (MSK) conditions now impact nearly one in...
Daraxonrasib Phase 3 Trial Results Signal a New Era for Pancreatic Cancer
The daraxonrasib pancreatic cancer trial results announced on 13 April 2026 represent what many in the oncology community are calling a landmark moment for one of medicine's most stubborn and lethal diseases. Revolution Medicines, a late-stage clinical oncology...
How Can At-Home Diagnostics and AI-Enabled Detection Drive Better Health?
The UK government’s 10 Year Health Plan sets a bold ambition for the NHS, shifting from analogue to digital, from hospital to community, and from cure to prevention. For the life sciences sector, this aligns closely with long standing priorities around earlier...
The Rising Reach of Black-Market Prescription Drugs in the UK
Despite common perceptions, the black market is no longer confined to underground, organised crime networks or obscure corners of the internet. In reality, this trade in illegal prescription drugs can be found in a local corner shop, hair salon, or even people’s own...
The Human Microbiome: An Interface Between Lifestyle, Metabolism & Health
For much of modern medicine, microorganisms have been largely viewed through a narrow lens, as agents of infection to be identified and then eliminated. This perspective, whilst undeniably important, captures only part of the story. Over the past two decades, advances...
How Behavioral Science and Machine Learning Can Transform Trial Adherence
It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people. Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a...
Weekly News Roundup | 13 April 2026
Life science news 13 April 2026: A record-breaking wave of M&A, an escalating GLP-1 pricing war and major FDA approvals define a landmark week for the global life science industry. Gilead Sciences announced on 7 April its acquisition of Munich-based antibody-drug...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.